HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach
Keywords: لنفوسیتروپروس; Immunotoxicology; Immunotoxicity; Immunomodulation; Immunosuppression; Carcinogenicity; Cancer; Risk assessment; CTL; cytotoxic T-lymphocytes; EBV; Epstein-Barr virus; FDA; Food and Drug Administration; HESI; Health and Environmental Sciences Institute;